|
Powered by Cell Signaling Technology |
Site Information |
---|
ALPAPRGsGtAsDDE SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 484347 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Treatments: |
References | |
---|---|
Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32
28852199 Curated Info |
|
Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257 Curated Info |
|
Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622 Curated Info |
|
Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604 Curated Info |